Company’s 36-month beta value is 0.76.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for VTYX is 62.50M, and currently, short sellers hold a 11.76% ratio of that floaft. The average trading volume of VTYX on April 16, 2025 was 1.20M shares.
VTYX) stock’s latest price update
Ventyx Biosciences Inc (NASDAQ: VTYX)’s stock price has soared by 0.91 in relation to previous closing price of 1.10. Nevertheless, the company has seen a gain of 21.36% in its stock price over the last five trading days. globenewswire.com reported 2025-04-01 that Appointment of seven recognized experts is validating for Ventyx’s NLRP3 Program — AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson’s disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today announced the appointment of seven additional internationally-recognized scientists and clinicians to its Scientific Advisory Board (SAB): Mo Lamkanfi, PhD, Luke O’Neill, PhD, Ted Dawson, MD, PhD, Martin Pomper, MD, PhD, Antonio Abbate, MD, PhD, Paul Cremer, MD and Don Frail, PhD. The new SAB members have made vital discoveries in understanding the role of the NLRP3 inflammasome in neuro- and systemic inflammation, and are at the forefront of clinical development in neurodegenerative and cardiometabolic diseases.
VTYX’s Market Performance
VTYX’s stock has risen by 21.36% in the past week, with a monthly drop of -21.28% and a quarterly drop of -42.78%. The volatility ratio for the week is 13.95% while the volatility levels for the last 30 days are 9.93% for Ventyx Biosciences Inc. The simple moving average for the past 20 days is -0.79% for VTYX’s stock, with a -45.65% simple moving average for the past 200 days.
Analysts’ Opinion of VTYX
Many brokerage firms have already submitted their reports for VTYX stocks, with Wells Fargo repeating the rating for VTYX by listing it as a “Overweight.” The predicted price for VTYX in the upcoming period, according to Wells Fargo is $16 based on the research report published on March 12, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see VTYX reach a price target of $12. The rating they have provided for VTYX stocks is “Outperform” according to the report published on March 12th, 2024.
Wells Fargo gave a rating of “Equal Weight” to VTYX, setting the target price at $8 in the report published on November 07th of the previous year.
VTYX Trading at -20.20% from the 50-Day Moving Average
After a stumble in the market that brought VTYX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.39% of loss for the given period.
Volatility was left at 9.93%, however, over the last 30 days, the volatility rate increased by 13.95%, as shares sank -18.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.64% lower at present.
During the last 5 trading sessions, VTYX rose by +21.36%, which changed the moving average for the period of 200-days by -53.56% in comparison to the 20-day moving average, which settled at $1.1189. In addition, Ventyx Biosciences Inc saw -49.32% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VTYX starting from Nuss John, who sale 1,887 shares at the price of $1.07 back on Apr 02 ’25. After this action, Nuss John now owns 467,226 shares of Ventyx Biosciences Inc, valued at $2,019 using the latest closing price.
Nuss John, the CHIEF SCIENTIFIC OFFICER of Ventyx Biosciences Inc, sale 21,119 shares at $2.36 during a trade that took place back on Dec 27 ’24, which means that Nuss John is holding 464,582 shares at $49,841 based on the most recent closing price.
Stock Fundamentals for VTYX
The total capital return value is set at -0.56. Equity return is now at value -54.27, with -48.36 for asset returns.
Based on Ventyx Biosciences Inc (VTYX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -12.12.
Currently, EBITDA for the company is -148.45 million with net debt to EBITDA at 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.97.
Conclusion
In a nutshell, Ventyx Biosciences Inc (VTYX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
